RPTX News and Press, Repare Therapeutics Inc. From 02/03/23

Cancer-focused biotech Repare Therapeutics ( NASDAQ: RPTX ) lost ~5% on Friday after Morgan Stanley downgraded it, citing concerns over an upcoming Phase 1 readout for the company’s PKMYT1 inhibitor RP-6306. The rating change comes as Repare ( RPTX ) runs Phase 1 studie...

Summary ARK Invest’s 13F portfolio value decreased from $14.35B to $11.54B this quarter. They increased Tesla, Ginkgo Bioworks, and Coinbase Global stakes while decreasing NVIDIA, Fate Therapeutics, and TuSimple Holdings during the quarter. The top three positions are Exact S...

Repare Therapeutics ( NASDAQ: RPTX ) said it received ~$1.5M (¥200M) research service payment from Japan's Ono Pharmaceutical ( OTCPK:OPHLF ) ( OTCPK:OPHLY ). The payment was due to achievement of a research trigger, under the companies' 2019 strategic partnership agr...

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that the Company has received an approximately $1.5 million (¥200 million) research service payment from Ono Pharmaceutical Co...

Repare Therapeutics press release ( NASDAQ: RPTX ): Q3 GAAP EPS of $1.71 beats by $2.12 . Revenue of $112.5M beats by $83.22M . Cash and cash equivalents and marketable securities: Cash and cash equivalents and marketable securities as of September 30, 2022 wer...

Early Phase 1 clinical data readout for RP-6306 is expected in the first half of 2023 Advancing camonsertib development with Roche under worldwide license and collaboration agreement IND-enabling studies for RP-2119, a Polθ inhibitor, currently underway and ...

Summary ARK Invest’s 13F portfolio value decreased from $16.91B to $14.35B this quarter. UiPath, Ginkgo Bioworks, and NVIDIA were increased while decreasing Spotify, Ionis Pharma, CRISPR Therapeutics, and Coinbase Global. The top three positions are Tesla Inc., Zoom Vid...

Summary Shares have posted a 40% loss over the past 12 months. I have added confidence in prospects for darovasertib in uveal melanoma given monotherapy activity as well as high ORR and PFS relative to competitors. MAT2A combination with Amgen's PRMT5 inhibitor has a compellin...

Summary Repare Therapeutics' shares have lost roughly half their value over the past year. Roche's deal for ATR inhibitor camonsertib validated the company's SNIPRx and STEP2 platform technologies, a unique take on the emerging field of synthetic lethality. The balance sheet i...

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate at two investor conferences in September. Details for the fir...